Citi Outlines Up to 410% Upside for Biomea Fusion and Syndax Pharmaceuticals
Citi equity research analyst Yigal Nochomovitz has assigned 'Strong Buy' outlooks to Biomea Fusion and Syndax Pharmaceuticals, citing major trial readouts and compounding product revenues.
